Healthcare News

Median overall survival of 19.9 months in patients with MGMT-unmethylated glioblastoma compares favorably with historical outcomesBPM31510 demonstrated a well-tolerated safety profile in combination...

61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ...

Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and...

Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with...

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million TARRYTOWN,...

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will...

BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company,...

Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39...

Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L)...

ORION CORPORATION STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS 26 October 2026 at 13.00 EET         Changes in Orion Group’s Executive Team as of 1 January 2027 To accelerate the...